Compare CVS Health Corp (CVS) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

TCPC trades at $3.94, down 1.25% today, with a bearish technical signal and mixed fundamentals. The company reported negative revenue and net income for 2025, though recent earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage, while analyst sentiment leans cautious with 69% hold ratings. The stock shows a low P/B ratio of 0.61, suggesting potential undervaluation relative to assets.

Outlook remains challenged by persistent negative profitability and revenue trends, with projected declines through 2026. The strategic review and dividend yield near 4.3% offer some upside, but risks include class action lawsuits and execution uncertainty. Investors should weigh the discount to book value against fundamental headwinds.